Drugs / AZD1163
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07276581 | Dec 2025 → Nov 2027 expected | rheumatoid arthritis | AstraZeneca | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06103877 Comparator | Nov 2023 → Jan 2026 | — | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD1163 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07276581 ↗ |
| Action | Inhibit | “inhibits the activity of extracellular peptidyl arginine deiminase 2 (PAD2) and peptidyl arginine deiminase 4 (PAD4) enzymes” NCT07276581 ↗ |
| Route | Intravenous | “through IV infusion” NCT06103877 ↗ |